Body Pharm BPC 157 5

Body Pharm BPC-157 5mg is a 5-milligram lyophilised research vial supplied by JCSG.org for South African researchers.

BPC-157 is not on SAHPRA's schedules and is treated in practice as an unregistered research chemical in South Africa [11][12]. It is sold strictly for laboratory and research purposes.

Key Takeaways

• The standalone 5mg lyophilised vial is the correct format for single-variable research; combination pens are only appropriate when co-administration of BPC-157 and TB-500 is intended
• BPC-157 is unscheduled and unregistered in South Africa, classified as a research chemical and not approved for human consumption
• No large completed human efficacy trial has been published; the evidence base is overwhelmingly preclinical
• Reconstitution requires bacteriostatic 0.9% sodium chloride or bacteriostatic water; concentration choice affects measurement precision and working duration

What Is Body Pharm BPC-157 5mg?

Body Pharm BPC-157 5mg is a 5-milligram lyophilised vial of the synthetic pentadecapeptide BPC-157, sold in South Africa as a research chemical and not a registered medicine [11]. The peptide is a 15-amino-acid sequence (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) originally identified within a protective fragment of human gastric juice, with a molecular weight of roughly 1,419 Da.

Why the 5mg lyophilised format matters

Lyophilised (freeze-dried) powder stabilises the peptide at ambient temperatures during shipping and gives the buyer control over final concentration at reconstitution. A 5mg vial is commonly reconstituted with 2 mL of bacteriostatic 0.9% sodium chloride or bacteriostatic water, yielding 2,500 mcg/mL. Using 1 mL gives 5,000 mcg/mL; 5 mL gives 1,000 mcg/mL [6][7]. The choice is a trade-off between measurement precision on a U-100 insulin syringe and total dosing volume per draw.

Some researchers prefer higher concentrations to reduce injection volume; others prioritise precision at lower concentrations. Your choice depends on your measurement instrument's smallest reliable graduation.

Standalone vial vs combination pen

A standalone 5mg vial gives a single, known peptide mass and clean per-mcg accounting. The Body Pharm BPC-157 & TB-500 32 Pen bundles two peptides in one device at a total mass of 32mg, with the BPC-157:TB-500 split not publicly published [unverified]. That makes per-mcg comparison against a standalone vial impossible without vendor disclosure.

Evidence and regulatory standing

BPC-157 has an extensive preclinical literature base but no large, completed human efficacy randomised controlled trial (RCT) with published results as of 2026. Two oral inflammatory bowel disease (IBD) trials are registered on ClinicalTrials.gov without posted results [12][14]. For wider background on the molecule, formats, and SA supply context, see the BPC-157 category overview.

Body Pharm BPC-157 5mg: Product Specifications

Specification	Body Pharm BPC-157 5mg
Peptide content	5 mg (5,000 mcg) per vial
Format	Lyophilised (freeze-dried) powder, single vial
Stated purity	Not publicly published on a primary Body Pharm technical sheet as of 2026 [unverified]
Certificate of Analysis	No public batch CoA located; availability on request unconfirmed [unverified]
Analytical method	Not disclosed publicly [unverified]; industry norm for research-grade BPC-157 is ≥98% by high-performance liquid chromatography (HPLC) with mass spectrometry (MS) identity [1][unverified]
Storage (sealed)	Typically −20°C for long-term stability (general peptide guidance, not a Body Pharm-specific claim)
Storage (reconstituted)	Typically 2–8°C for up to ~3 weeks in bacteriostatic diluent (general guidance) [8]
Reconstitution	Not included — buyer supplies bacteriostatic 0.9% saline or bacteriostatic (BAC) water [8]
Consumables	No syringes, alcohol swabs, or diluent in the box
Current price (ZAR)	Shown in the buy box

Standalone vial versus combination pen

This 5mg vial is a different SKU from the Body Pharm BPC-157 & TB-500 32 Pen, where the BPC-157:TB-500 mg split is not publicly disclosed [unverified]. Per-mcg comparison is not possible without vendor confirmation. For format context across the category, see the BPC-157 category overview.

Format Comparison: Standalone Vial vs Combination Pen

For single-variable research, a standalone 5 mg lyophilised vial is the correct format. A combination pen is only appropriate when BPC-157 and TB-500 effects do not need to be isolated.

The two formats differ on dosing control, reconstitution, and experimental design.

Attribute	Standalone 5 mg vial	BPC-157 + TB-500 combo pen (e.g. Body Pharm 32 mg)
State on arrival	Lyophilised powder, requires reconstitution (commonly 2 mL bacteriostatic saline → 2,500 mcg/mL) [8]	Pre-filled, pre-measured device
Dosing precision	Researcher sets concentration and volume	Fixed per-click dose set by manufacturer
Single-variable isolation	Yes — BPC-157 only	No — two active peptides co-administered
Published mg split	N/A	Not publicly verifiable for Body Pharm [unverified]
Best for	Controlled protocols, dose-response work	Convenience-led use where co-administration is intended

TB-500 is a synthetic fragment of Thymosin Beta-4 studied preclinically for actin sequestration and angiogenesis. No completed human efficacy trials have been located as of 2026 [unverified]. Co-administering it with BPC-157 confounds attribution: any observed outcome cannot be cleanly assigned to either peptide.

The Body Pharm BPC-157 & TB-500 32 Pen page covers the device specifics if the combo format fits your design. For standalone-vial alternatives, the BPC-157 category overview lists every 5 mg and 10 mg SKU in the same range.

SAHPRA Classification: What It Means for SA Buyers

BPC-157 is not registered as a medicine and does not appear in the published Schedules to the Medicines and Related Substances Act 101 of 1965 (as amended by Act 14 of 2015) as of 2026. This places it outside the scheduled-medicines framework and into what local suppliers commonly label a "research chemical" [unverified]. Verify current status directly with SAHPRA (sahpra.org.za) before procurement, as scheduling can change without retail-side notice.

The South African Health Products Regulatory Authority (SAHPRA) is the statutory regulator for medicines, medical devices and related health products in South Africa. Because BPC-157 has no Medicines Control Council or SAHPRA registration dossier, it cannot lawfully be marketed, advertised, or sold for human use. Any human-use supply route would need to go through Section 21 named-patient authorisation or a compliant individual-prescription compounding arrangement.

What "research chemical" means in practice

Practical question	Position as of 2026
Can it be procured for in vitro / laboratory research?	Yes, by entities with a legitimate research purpose [unverified]
Can it be sold or marketed for human consumption?	No — would constitute supply of an unregistered medicine [unverified]
Is it on a SAHPRA Schedule (S1–S6)?	Not located on published Schedules as of 2026 — verify with SAHPRA [unverified]
Is it World Anti-Doping Agency (WADA)-prohibited for competing athletes?	Yes, listed as prohibited [1]
Documentation buyers should retain	Written record of research purpose, institutional affiliation where applicable, supplier invoice and batch CoA

Disclaimer

For research use only. This page is intended for laboratory research buyers. Nothing here is medical advice, a therapeutic claim, or an endorsement of human use. BPC-157 is not approved for human consumption in South Africa. Confirm current SAHPRA scheduling and any import requirements with SAHPRA or a qualified South African regulatory affairs professional before ordering.

For SKU-level specifications across the range, the BPC-157 category overview lists every 5 mg and 10 mg vial currently catalogued on JCSG.org.

BPC-157 Research Overview: What the Preclinical Data Shows

The BPC-157 evidence base is overwhelmingly preclinical: rodent and in vitro studies dominate. No large, completed, peer-reviewed human efficacy RCT has been published as of 2026 [10][11]. Two oral BPC-157 trials for inflammatory bowel disease are registered on ClinicalTrials.gov without posted results. A small phase 1 safety study and a roughly 12-participant intra-articular knee study exist but are methodologically weak [10][4].

The colloquial "wolverine peptide" label circulates in vendor copy and forum discussion. It is not a formal scientific designation and does not appear in the peer-reviewed pharmacology literature.

Studied mechanisms in preclinical models

Research area	What the preclinical literature examines	Evidence status (2026)
Tendon, ligament, muscle, bone repair	Rodent injury models assessing tissue recovery markers	Preclinical only; no human RCT outcomes [11]
Gastrointestinal	Gastric ulcer healing in rats — the original discovery context for the pentadecapeptide	Preclinical; two human IBD trials registered, results not posted [10][12]
Angiogenesis	Studied promotion of new blood vessel formation in animal and in vitro models	Preclinical only [12]
Inflammation modulation	Studied effects on inflammatory cytokine signalling in rodent models	Preclinical only [12]

A 2021 Frontiers in Pharmacology review references earlier human work in ulcerative colitis and multiple sclerosis, but these pre-2020 datasets are small and have not driven regulatory adoption anywhere [12]. Animal findings do not translate automatically to human outcomes. Nothing in the current literature supports therapeutic claims at the point of sale.

For buyers weighing format against the research stage of the molecule, the BPC-157 category overview catalogues every 5 mg and 10 mg standalone vial available on JCSG.org. The Body Pharm BPC-157 & TB-500 32 Pen listing covers the combination device.

Reconstitution and Storage: Research Protocol Notes

For research use only. The notes below describe general lyophilised peptide handling and are not dosing instructions for human use.

Reconstitution of a 5 mg lyophilised BPC-157 vial in research settings most commonly uses 2 mL of bacteriostatic 0.9% sodium chloride or bacteriostatic water for injection, yielding 2.5 mg/mL (2,500 mcg/mL) [1]. Bacteriostatic diluents contain 0.9% benzyl alcohol, which permits multi-draw use from the same vial across the working window. Sterile water without preservative is generally reserved for single-use reconstitution.

Concentration scales linearly with diluent volume. Adding 1 mL to a 5 mg vial gives 5 mg/mL (5,000 mcg/mL); 5 mL gives 1 mg/mL (1,000 mcg/mL) [1]. Lower concentrations improve measurement precision at small draw volumes; higher concentrations reduce injection volume. Researchers typically select the ratio that matches their measurement instrument's smallest reliable graduation.

Handling steps

1. Allow both vials to reach room temperature before mixing.
2. Wipe both stoppers with a fresh alcohol swab.
3. Draw the chosen volume of bacteriostatic diluent into a syringe.
4. Inject the diluent slowly down the inner wall of the BPC-157 vial, not directly onto the powder cake.
5. Do not shake. Swirl gently until the solution is clear.

Storage

State	Temperature	Light	Working window
Lyophilised (sealed)	−20 °C	Protect from light	Until labelled expiry
Reconstituted	2–8 °C (refrigerated)	Protect from light	Typically 28–30 days in research handling guides [1]

The BPC-157 category overview lists the standalone 5 mg and 10 mg vial formats that follow this reconstitution protocol directly.

Related Peptides Available on JCSG.org South Africa

Researchers working with BPC-157 often run parallel protocols using TB-500, GHK-Cu, or CJC-1295. All are available on JCSG.org for South African researchers.

TB-500 and combination formats

TB-500 (thymosin beta-4 fragment) is frequently paired with BPC-157 in soft-tissue repair research because both peptides are studied for connective-tissue healing in preclinical models. The Body Pharm BPC-157 & TB-500 32 Pen consolidates both peptides into a single pre-measured device, removing one reconstitution step from the workflow.

GHK-Cu and CJC-1295

GHK-Cu (copper tripeptide-1) is studied for skin and connective-tissue repair endpoints and is commonly run alongside BPC-157 in dermal research models because both target tissue remodelling pathways. CJC-1295 sits in a different research lane, used in growth hormone axis investigations rather than localised repair.

Full catalogue

The complete BPC-157 category overview lists standalone 5 mg and 10 mg vials. Browse the full range of Body Pharm research peptides available for South African delivery at JCSG.org/za/peptides/.

Frequently Asked Questions